Filing Flows › Amphastar Pharmaceuticals (AMPH) › R&D spending
Amphastar Pharmaceuticals (AMPH) R&D spending by quarter
Amphastar Pharmaceuticals' R&D spending was $20.1M in Q3 2026 (third quarter 2026), -9% from Q2 2026. Over the last 7 quarters it ranged from $20.1M (Q3 2026) to $26.7M (Q1 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $20.1M | -9% | -10% |
| Q2 2026 | $22.2M | -17% | +10% |
| Q1 2026 | $26.7M | +15% | +33% |
| Q4 2025 | $23.3M | +4% | — |
| Q3 2025 | $22.4M | +11% | — |
| Q2 2025 | $20.1M | -0.1% | — |
| Q1 2025 | $20.1M | — | — |
Q3 2026 at a glance
Amphastar Pharmaceuticals, Q3 2026: revenue $208M (+8% year over year), operating margin 24.5%, net earnings $37.8M, operating cash flow $43.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is Amphastar Pharmaceuticals' R&D spending?
Amphastar Pharmaceuticals' R&D spending was $20.1M in Q3 2026 (third quarter 2026), -9% from Q2 2026.
How has Amphastar Pharmaceuticals' R&D spending changed?
Over the last 7 quarters it ranged from $20.1M (Q3 2026) to $26.7M (Q1 2026).
Q3 2026 results → · How Amphastar Pharmaceuticals makes money →